List of Rydapt drug patents
Rydapt is owned by Novartis.
Rydapt contains Midostaurin.
Rydapt has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rydapt are:
- US8222244
Rydapt was authorised for market use on 28 April, 2017.
Rydapt is available in capsule;oral dosage forms.
Rydapt can be used as treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl).
The generics of Rydapt are possible to be released after 02 December, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(4 months ago) | |
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(5 years from now) | |
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)
Dosage: CAPSULE;ORAL
RYDAPT family patents
10
United States
4
China
4
European Union
3
Japan
3
Canada
3
Australia
2
Portugal
2
Germany
2
Spain
2
Brazil
2
Austria
2
Mexico
2
Taiwan, Province of China
2
Korea, Republic of
2
Hong Kong
2
Hungary
2
Slovenia
2
Poland
2
Denmark
1
Russia
1
New Zealand
1
Norway
1
South Africa
1
Cyprus
1
Luxembourg
1
Israel
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic